Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
Jubilant Pharmova Limited received a Show Cause Notice on August 31, 2026, from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, concerning alleged GST liabilities for the financial year 2022-2023. The notice proposes a total demand of ₹87.31 crore, including tax, interest, and penalty. Separately, on August 27, 2026, Jubilant Generics Limited, a wholly-owned subsidiary, received a Show Cause Notice from the CGST Division, Uttarakhand, proposing a GST demand of ₹52.75 crore plus an equal penalty for alleged inadmissible IGST refunds during FY 2020-21 and 2021-22. In both instances, the company stated its intention to file detailed replies contesting the notices, asserting they are factually incorrect and expecting no financial or operational impact.
At the 48th AGM on August 26, 2026, Jubilant Pharmova Limited passed all four resolutions. These included the declaration of a dividend of ₹5 per equity share for the financial year ended March 31, 2026, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia. The company also adopted audited standalone and consolidated financial statements for FY 2025-26. During the meeting, Chairman Shyam Sunder Bhartia reported consolidated revenue growth of 14% to ₹83 billion in FY26 and mentioned strategic progress on new manufacturing lines at the Spokane facility.
As of September 18, 2026, Jubilant Pharmova's stock has shown varied returns across different periods. It has returned 23% in the last month and 24% in the last six months. Over the last year, the stock has seen a return of -4%. Looking at longer timeframes, the return over the last 10 years was 17%, and since the start of trading, it was -1%.
On a daily timeframe as of September 18, 2026, technical indicators suggest a bullish trend, with the Supertrend indicator at 939.38 and a 'bullish' direction. The closing price of ₹1065.4 is above both the 20-day Exponential Moving Average (EMA) of 971.24 and the 50-day EMA of 952.96. However, on a monthly timeframe, the Supertrend indicator is at 1336.25 with a 'bearish' direction, indicating a different trend over a longer period.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹2,229.40 crore | PEAK₹2,290 crore | ₹2,122.50 crore | ₹1,966.40 crore | ₹1,900.70 crore |
| Profit Before Tax | ₹86.40 crore | ₹176 crore | ₹93.50 crore | PEAK₹190.40 crore | ₹154.50 crore |
| Profit Loss For Period | ₹56.40 crore | ₹119.30 crore | ₹55.80 crore | PEAK₹119.90 crore | ₹102.50 crore |
| Finance Costs | ₹54.20 crore | PEAK₹56.50 crore | ₹56.10 crore | ₹50.20 crore | ₹49 crore |
| Tax Expense | ₹30 crore | ₹56.70 crore | ₹37.60 crore | PEAK₹70.40 crore | ₹51.90 crore |
| Other Expenses | PEAK₹479.20 crore | ₹470.50 crore | ₹410.30 crore | ₹392.30 crore | ₹401.80 crore |
Revenue from operations was ₹2,229.40 crore, up 17.3% from ₹1,900.70 crore in Q1 FY2025‑26. On a sequential basis, revenue declined 2.6% from ₹2,290 crore in the immediately preceding quarter (Q4 FY2025‑26).
Other comprehensive income turned negative at –₹19.10 crore, compared with a positive ₹41.10 crore in the year‑earlier quarter and ₹281.90 crore in Q4. This swing drove total comprehensive income down to ₹37.30 crore, a decline of 74% from ₹143.60 crore year‑on‑year and 91% from ₹401.20 crore sequentially.
Basic earnings per share fell to ₹3.57, down 45% from ₹6.49 in Q1 FY2025‑26 and 53% from ₹7.55 in Q4. Diluted EPS moved similarly, to ₹3.56.
Revenue grew 17% year‑on‑year, but profit fell sharply because expense increases — notably a 19% rise in other expenses — outpaced revenue growth. The quarter’s result was further reduced by a large negative swing in other comprehensive income, highlighting the combined effect of rising operating costs and non‑operating volatility on overall profitability.
Exchange disclosures and regulatory announcements for Jubilant Pharmova.
On August 31, 2026, Jubilant Pharmova Limited received a Show Cause Notice from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore regarding alleged GST liabilities for the financial year 2022–2023. The notice proposes a total demand of Rs. 87.31 crore, comprising Rs. 33.58 crore in tax, Rs. 20.15 crore in interest, and Rs. 33.58 crore in penalty based on issues such as ineligible input tax credit and E-waybill discrepancies. The company intends to file a detailed reply contesting the notice as factually incorrect and expects no financial or operational impact.
On August 27, 2026, Jubilant Generics Limited received a Show Cause Notice from the CGST Division, Uttarakhand, proposing a GST demand of Rs. 52.75 crore plus an equal penalty for alleged inadmissible IGST refunds during FY 2020-21 and 2021-22. The notice relates to violations of Rule 96(10) of the CGST Rules, 2017 concerning the Advance Authorisation scheme, with interest remaining unquantified. Jubilant Pharmova Limited's wholly-owned subsidiary intends to file a detailed reply contesting the demand, asserting that the notice is factually incorrect and expecting no financial or operational impact.
MEETING DATE : 26-AUG-2026
Jubilant Pharmova Limited held its 48th Annual General Meeting on August 26, 2026, where all four resolutions were passed with requisite majorities, including the declaration of a dividend of Rs. 5 per equity share for the financial year ended March 31, 2026, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia by rotation. The meeting, conducted via video conferencing with 86 members present representing over 707 million shares, also saw the adoption of audited standalone and consolidated financial statements for FY 2025-26. Chairman Shyam Sunder Bhartia highlighted consolidated revenue growth of 14% to ₹83 billion in FY26 and outlined strategic progress on new manufacturing lines at the Spokane facility.
Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A |SUBJECT: General Updates
On August 17, 2026, Jubilant Pharmova Limited shareholders passed special resolutions to re-appoint Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, including their remuneration. The voting results, scrutinized by Rupinder Singh Bhatia, showed 99.81% assent for the first resolution with 12,70,16,638 votes in favor and 0.19% dissent, while the second resolution received 99.87% assent with 12,70,99,995 votes in favor and 0.13% dissent. The remote e-voting process concluded on August 17, 2026, at 5:00 p.m., with a cut-off date of July 10, 2026.
Jubilant Pharmova Limited published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in Financial Express (English) and Hindustan & Jansatta (Hindi) newspapers on August 11, 2026. The results were approved by the Board of Directors on August 10, 2026.
Recent market and company developments associated with Jubilant Pharmova.
Securities in F&O Ban:
From HDFC Bank's succession plan to Tata Sons' potential listing and its impact on listed Tata Group stocks and the impact of SEBI's consultation paper on CAS on BSE, Angel One and other brokers, these are the stocks you should watch out for going into Tuesday's trading session.
Shares of Jubilant Pharmova Ltd ended at ₹1,025.65, down by ₹0.050, or 0.0049%, on the BSE.
Market expert Raja Venkatraman shares his top stock picks for 8 September. Here’s his technical outlook and trade strategy.
Jubilant Generics received a Rs 105.5 crore GST show-cause notice from Uttarakhand authorities. The notice alleges improper availment of tax refund and Advance Authorisation Scheme benefits. This action pertains to the fiscal years 2020-21 and 2021-22. The company plans to contest the notice and file a detailed reply soon. Jubilant Pharmova expects no significant financial or operational impact.
Buzzing Stocks
Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover...
RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme.
Comprehensive Section Breakdown for Jubilant Pharmova
Strategic Vision: Integrated global pharmaceutical company with diverse business segments.
• Global presence with manufacturing facilities in regulated markets.
• Integrated operations across multiple pharmaceutical business segments.
• Network of radio-pharmacies across the United States.
Jubilant Pharmova Limited reported a 17% year-on-year increase in revenue to ₹2,229.40 crore in the first quarter of FY2026‑27, but profit before tax fell 44% to ₹86.40 crore and net profit declined 45% to ₹56.40 crore. Other expenses rose 19%, outpacing revenue growth, while a sharp negative swing in other comprehensive income caused total comprehensive income to drop 74% year-on‑year.
Profit before tax fell to ₹86.40 crore, down 44.1% year‑on‑year from ₹154.50 crore and 50.9% from ₹176 crore sequentially. Net profit showed a similarly steep decline, dropping to ₹56.40 crore — 45% below the prior‑year quarter and 52.7% below the preceding quarter.
The profit‑before‑tax margin contracted to 3.9% from 8.1% in Q1 FY2025‑26. The effective tax rate (tax expense as a percentage of profit before tax) rose to 34.7% from 33.6% a year earlier and 32.2% in Q4, contributing modestly to the lower net profit.
Other expenses, a major cost item, increased 19.3% year‑on‑year to ₹479.20 crore from ₹401.80 crore. As a percentage of revenue, other expenses moved from 21.1% to 21.5%, absorbing a slightly larger share of sales. Sequentially, they edged up 1.8% from ₹470.50 crore.
Finance costs were ₹54.20 crore, 10.6% higher than ₹49 crore in Q1 FY2025‑26, though they were 4.1% lower than the ₹56.50 crore recorded in the preceding quarter. The year‑on‑year increase added to the expense burden.
Category: Manufacturing
The Radiopharma business segment is involved in the manufacturing and supply of radiopharmaceuticals, operating a network of 46 radio-pharmacies across the United States.
Category: Manufacturing
This segment focuses on the manufacturing and supply of allergic extracts and venom products, supplied to markets in the United States, Canada, Europe, and Australia.
Category: B2B Services
The company provides manufacturing services for sterile fill and finish injectables, including liquid and lyophilization forms, and an ophthalmic portfolio.
Category: B2B Services
The CRDMO business integrates Drug Discovery Services and CDMO-API operations, providing contract research and development and manufacturing of Active Pharmaceutical Ingredients.
Category: Manufacturing
The Generics business segment is involved in the manufacturing and supply of generic pharmaceutical products.
Category: Biopharmaceutical
Jubilant Therapeutics, part of this business, is a biopharmaceutical company focused on developing therapies for oncology and auto-immune disorders.
Core Thesis: The company leverages its integrated pharmaceutical capabilities across diverse business segments to serve global markets.
• Global Manufacturing Footprint: Operates six manufacturing facilities serving regulated markets including the USA and Europe. • Integrated Business Model: Combines Radiopharma, Allergy Immunotherapy, CDMO, CRDMO, Generics, and Proprietary Novel Drugs segments. • Research and Development: Supports contract research and development through research centers in India and focuses on novel drug development.